← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Intra-Cellular Therapies, Inc.
New York, NY
$21,930,267
Total funding
8
Grants
Funding over time
peak $11.4M · FY2005–21$20M$15M$10M$5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
Funding mix
By agency
NIH$11,511,088 · 6
DOD$10,419,179 · 2
By mechanism
—$10,419,179 · 2
UG3$6,166,204 · 1
R44$4,243,293 · 1
R43$947,081 · 3
R21$154,510 · 1
Investigators at Intra-Cellular Therapies, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
MOLECULAR MECHANISMS IN THE CO-MORBIDITY OF DEPRESSION, SCHIZOPHRENIA AND ANXIETY AND THEIR RELEVANCE TO PARKINSON'S DISEASE$10,423,433
· FY2008 · Department of the Army
Development of ITI-333, a μ-opioid Receptor Partial Agonist and 5HT2A and D1 Receptor Antagonist, for the Treatment of Opioid Use Disorders$3,249,130
UG3 · FY2019 · DA
Development of ITI-333, a μ-opioid Receptor Partial Agonist and 5HT2A and D1 Receptor Antagonist, for the Treatment of Opioid Use Disorders$2,917,074
UG3 · FY2021 · DA
Novel PDE Inhibitors for Treatment of Cognitive Dysfunction in Schizophrenia$968,007
R44 · FY2008 · MH
Novel PDE Inhibitors for Treatment of Cognitive Dysfunction in Schizophrenia$964,601
R44 · FY2010 · MH
Novel PDE Inhibitors for Treatment of Cognitive Dysfunction in Schizophrenia$964,465
R44 · FY2009 · MH
Novel PDE Inhibitors for Depression$463,752
R44 · FY2005 · MH
Novel PDE Inhibitors for Depression$463,329
R44 · FY2007 · MH
Novel PDE Inhibitors for Depression$419,139
R44 · FY2006 · MH
Casein Kinase 1 Inhibitors for Treatment of Autism$349,610
R43 · FY2014 · MH
Development of PDE2 Inhibitors for Treatment of Anxiety/Depression in Autism/Schizophrenia$348,094
R43 · FY2016 · MH
PHOSPHOPROTEOME ANALYSIS OF ANTIDEPRESSANT DRUGS$249,377
R43 · FY2003 · MH
Synthesis and Evaluation of Novel PET NET Tracers$154,510
R21 · FY2007 · MH
DEVELOPMENT OF A ROBUST PHOSPHO-PROTEIN INTERACTION MAP USEFUL FOR DIAGNOSIS OF NEURODEGENERATIVE DISEASES$-4,254
· FY2011 · Department of Defense